Denali Therapeutics Inc. (DNLI)
$
17.99
+0.62 (3.45%)
Key metrics
Financial statements
Free cash flow per share
-2.3828
Market cap
2.6 Billion
Price to sales ratio
0
Debt to equity
0.0479
Current ratio
9.7908
Income quality
0.7976
Average inventory
0
ROE
-0.4633
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Denali Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic candidates for neurodegenerative diseases based in the United States. The company recorded a notable revenue of $0.00 showcasing its steady growth in a challenging industry. The earnings per share (EPS) is reported at -$2.57 indicating the company's profitability on a per-share basis, despite facing operational challenges. Its operating expenses amount to $487,341,000.00 encompassing various operational costs incurred during development. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in its ongoing and future projects. However, the company reported a net loss of -$422,773,000.00 indicating challenges in its operations as it continues to invest in innovative therapies. Denali offers a range of therapeutic candidates, such as the LRRK2 inhibitor product candidate BIIB122/DNL151, which is currently in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. Additionally, the company is progressing with DNL310 in Phase I/II trials for Hunter syndrome, and DNL343 in phase 1 trials for amyotrophic lateral sclerosis (ALS). Completing a phase I clinical trial, AR443820/DNL788 targets ALS, multiple sclerosis (MS), and Alzheimer's disease, while SAR443122/DNL758 is in phase II trials for cutaneous lupus erythematosus. The company collaborates with notable partners including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, and the Michael J. Fox Foundation, among others, to enhance its research and development efforts. In the financial landscape, the stock is affordable at $12.75 suitable for budget-conscious investors looking to enter the biopharmaceutical market. It has an average trading volume of 2,178,504.60 indicating moderate liquidity, which may appeal to a broad range of investors. With a mid-range market capitalization of $2,637,716,070.00 the company is a steady performer that plays an essential role in the biopharmaceutical industry, contributing significantly to the overall market landscape. Denali Therapeutics belongs to the Healthcare sector, driving innovation and growth, underscoring its commitment to addressing unmet medical needs in neurodegenerative diseases and beyond.
Is Denali Therapeutics Inc. (DNLI) a good investment?
Investing in Denali Therapeutics Inc. (DNLI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Denali Therapeutics Inc. (DNLI)'s stock forecast?
Analysts predict Denali Therapeutics Inc. stock to fluctuate between $10.57 (low) and $24.35 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Denali Therapeutics Inc.'s market capitalization?
As of 2025-12-12, Denali Therapeutics Inc.'s market cap is $2,637,716,070, based on 146,662,000 outstanding shares.
How does Denali Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Denali Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Denali Therapeutics Inc. (DNLI) stock?
To buy Denali Therapeutics Inc. (DNLI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNLI. Place an order (Market, Limit, etc.).
What is the best time to invest in Denali Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Denali Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.57 | Growth: 142.45%.
Where can I find Denali Therapeutics Inc.'s investor relations reports?
Visit https://www.denalitherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Denali Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Denali Therapeutics Inc. stock?
All-time high: $56.80 (2021-09-02) | All-time low: $10.57 (2025-04-07).
What are the key trends affecting Denali Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about December 11, 2025, subject to satisfaction of customary closing conditions.
zacks.com
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
seekingalpha.com
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
seekingalpha.com
Denali Therapeutics Inc. ( DNLI ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Ryan Watts - Co-Founder, President, CEO & Director Alexander Schuth - Co-Founder, CFO, COO & Secretary Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Okay. We're going to get started with our next session.
zacks.com
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
benzinga.com
The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.'s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
zacks.com
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The Prescription Drug User Fee Act (PDUFA) target date has been extended from January 5, 2026, to April 5, 2026.
zacks.com
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
seekingalpha.com
Denali Therapeutics Inc. (NASDAQ:DNLI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Ryan Watts - Co-Founder, President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech equity research at the firm.
See all news
